BC Week In Review | May 18, 2017
Clinical News

Formation starts Phase I/IIa of AVID100 in solid tumors

Formation Biologics Inc. (Austin, Texas) began an open-label, U.S. Phase I/IIa trial of AVID100 in about 80 patients with advanced EGFR-positive solid tumors. Patients will receive escalating doses of IV AVID100 every 3 weeks in...
Items per page:
1 - 1 of 1